Conatus Pharmaceuticals Total Liabilities

Conatus Pharmaceuticals (CNAT) currently reports a total liabilities of $1.1M as of March 2020. That compares with $19M in the prior-year period — down 93.8% year over year. Use the charts on this page to explore Conatus Pharmaceuticals's total liabilities history and peer comparisons.

Conatus Pharmaceuticals's total liabilities decreased from $19M to $1.1M — a 93.8% year-over-year decrease (period ending March 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Conatus Pharmaceuticals reported $1.1M in total liabilities as of March 2020. That compares with $19M in the prior-year period — down 93.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Conatus Pharmaceuticals, and consider following CNAT for alerts when major investors trade the stock.

Conatus Pharmaceuticals is classified in the Healthcare sector. On total liabilities, it currently shows $1.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CNAT with unrelated industries.